Murchinson’s Tonix Pharmaceuticals TNXP Stock Holding History

Murchinson’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-25	Closed	-$5.05M	–	93
2022 Q2	$5.05M	Buy	+25	New	+$1.84M	0.97%	12

Other funds holding TNXP

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Murchinson's TNXP Position: Q3 2022 in Review

Murchinson sold out of Tonix Pharmaceuticals (TNXP) in Q3 2022, closing a stake of 25 shares — an estimated $5.05M sold.

Murchinson first reported a position in TNXP in Q2 2022 and held it in 1 quarter. The position peaked at $5.05M in Q2 2022. 19 funds tracked by Wall St. Rank hold TNXP as of Q3 2022.

Murchinson reported no remaining Tonix Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Murchinson sold 25 Tonix Pharmaceuticals shares in Q3 2022, an estimated $5.05M.
Murchinson first reported a position in Tonix Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Murchinson's Tonix Pharmaceuticals position peaked at $5.05M in Q2 2022.
19 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2022.

Based on Murchinson's 13F filing for Q3 2022, filed 14 Nov 2022.